Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults [Yahoo! Finance]
Ardelyx, Inc. (ARDX)
Last ardelyx, inc. earnings: 3/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ardelyx.com/investor-relations
Company Research
Source: Yahoo! Finance
and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA ® (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults. “We are thrilled to share new data on the safety and efficacy of IBSRELA in adults with IBS-C at this year's DDW Conference as we seek to continually elucidate its potential benefit in this patient population. These data provide additional information for both patients and prescribers as they consider IBSRELA as a potential new treatment option when symptoms of IBS-C persist despite current therapies,” said Laura Williams, MD MPH, chief medical officer of Ardelyx. “These analyses provide further evidence of the r
Show less
Read more
Impact Snapshot
Event Time:
ARDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARDX alerts
High impacting Ardelyx, Inc. news events
Weekly update
A roundup of the hottest topics
ARDX
News
- Ardelyx, Inc. (NASDAQ: ARDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Ardelyx, Inc. Reports Employment Inducement GrantsGlobeNewswire
- Ardelyx, Inc. (NASDAQ: ARDX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.MarketBeat
- Ardelyx slips as commercial chief departs [Seeking Alpha]Seeking Alpha
- Ardelyx, Inc. (NASDAQ: ARDX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.MarketBeat
ARDX
Earnings
- 5/2/24 - Beat
ARDX
Sec Filings
- 6/13/24 - Form 144
- 6/13/24 - Form 144
- 6/7/24 - Form 4
- ARDX's page on the SEC website